Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

NCT: NCT06192758 · ACTIVE_NOT_RECRUITING

NCT IDNCT06192758
StatusACTIVE_NOT_RECRUITING
Start Date2024-04-15
Completion2032-10

Brief Summary

The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.

Frequently Asked Questions

What is Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device?

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device is a clinical trial registered under NCT06192758. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06192758?

The current status of NCT06192758 (Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device) is: ACTIVE_NOT_RECRUITING.

When did Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device start?

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device started on 2024-04-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑